The change from baseline in 2-hour pruritus score was shown to be statistically noninferior from IV cetirizine to IV diphenhydramine, in favor of IV cetirizine.
Through Palvella's proprietary QTORIN formulation, PTX-022 targets basal keratinocytes, which harbor the mutant keratin genes that cause PC.
Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.
The FDA's approval was supported by data from analytical, preclinical, and clinical research showing that Hyrimoz matched the reference product's safety, efficacy, and quality.
Oral medications for the treatment of acne including dosing for antibiotics, retinoids, and contraceptives.
Analyses presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2018 meeting, showed that compared with non-targeted treatments like apremilast, Ilumya was found to be the most cost-effective.
The researchers found that tretinoin 0.05% lotion demonstrated statistically significant superiority to vehicle in reducing inflammatory and non-inflammatory lesion counts (both P<.001) at week 12, as well as improving acne severity (P<.001).
The approval of Bryhali was based on data from 2 randomized, double-blind studies conducted in 430 patients with moderate to severe plaque psoriasis.
The approval was based on Phase 3 data from 2 studies in ABSSSI, where treatment with Nuzyra was compared with linezolid, and 1 study in CABP comparing Nuzyra with moxifloxacin. Across all 3 trials, Nuzyra was found to be effective and generally safe and well-tolerated.
The approval was based on data from 2 large, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials involving patients with moderate to severe facial acne vulgaris.
The approval was based on data from 2 open-label studies where patients with metastatic CSCC or locally advanced CSCC who were not candidates for curative surgery or curative radiation received Libtayo 3mg/kg intravenously every 2 weeks for up to 48 weeks or up to 96 weeks until disease progression, unacceptable toxicity, or completion of planned treatment.
The patient, a 42-year-old female with systemic lupus erythematosus treated with mycophenolate mofetil and prednisone, reported swelling and pain in the fifth finger of her left hand for about 1-week.
At Week 8 post-treatment, 92% of the burn sites treated with RECELL System achieved complete healing vs 85% of sites treated with standard-of-care, demonstrating non-inferiority.
The structure of contezolid was designed to potentially reduce the risk of hematological toxicity associated with this class of antibiotics.
The Phase 3 trial enrolled 251 patients aged 12-17 years old with moderate-to-severe atopic dermatitis, whose disease was not adequately controlled by prescription topical medications or for whom topical treatment was medically inadvisable.
The Phase 3 study (N=318) enrolled patients aged 18 to 78 years with moderate-to-severe chronic plaque psoriasis who had not previously received treatment with ≥1 biologic.
Preliminary results from a Phase 1b proof-of-concept study showed that SYNT001 was associated with clinical improvement (as measured by Pemphigus Disease Area Index score) and induced a rapid reduction in lgG and circulating immune complex levels.
To investigate the effectiveness of CAM modalities in the treatment of plaque psoriasis, researchers searched several databases to identify studies where CAM was used as an intervention.
The case involved a 55-year-old female patient who had been admitted to the hospital after suffering injuries from a car accident.
PF-06651600 is an investigational oral Janus kinase 3 (JAK3) inhibitor that is being evaluated in a Phase 2 study which will assess the treatment based on changes from baseline in Severity of Alopecia Tool (SALT) score.
Its long-term safety was evaluated in a phase 3, multicenter, open-label study of 555 adults with moderate to severe plaque psoriasis.
The Company is seeking approval for the treatment to temporarily improve the appearance of moderate to severe glabellar lines.
Systemic therapy treatment chart for psoriasis patients generally reserved for those with chronic plaque psoriasis without psoriatic arthritis who are candidates for systemic treatment when UV therapy is not available.
The approval was based on 2 double-blind clinical trials involving 1640 patients 9 years of age and older with moderate to severe acne vulgaris.